Saint Louis Hospital (Bangkok)

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Retrieved on: 
Friday, September 22, 2023
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Interim, Lymphoma, Cutaneous T-cell lymphoma, KIR3DL2, MF, EORTC, Euronext Paris, Asilomar International Conference on Climate Intervention Technologies, IPH, Patient, Lymph, IPHA, Node, Saint Louis Hospital (Bangkok), Conference, ORR, Caregiver, Pharmaceutical industry, Cryptocurrency, Vaccine, CTCL

The data were previously presented at the 17th International Conference on Malignant Lymphoma , in Lugano (Switzerland), in June 2023.

Key Points: 
  • The data were previously presented at the 17th International Conference on Malignant Lymphoma , in Lugano (Switzerland), in June 2023.
  • Lymph Node assessment is an important component of staging and response assessment in CTCL (cutaneous T cell lymphomas).
  • “We are pleased to present the interim results of the Phase 2 TELLOMAK study based on updated guidelines at the EORTC Cutaneous Lymphoma Tumour Group Meeting.
  • The higher global ORR according to updated lymph node further supports the ongoing development of lacutamab in T cell lymphomas.

JALON THERAPEUTICS RAISES NEARLY 2 MILLION EUROS TO DEVELOP A DISRUPTIVE APPROACH IN ONCOLOGY

Retrieved on: 
Friday, December 16, 2022
Peptide, Protein, Drug discovery, NOA, PIA, Escape Room, Antibody, Saint Louis Hospital (Bangkok), Phenotype, Cancer, Laboratory, Business Angel Network of Southeast Asia, France, Survival, Research, Therapy, INSERM, Pharmaceutical industry, Vaccine, Family

Created in 2021, Jalon Therapeutics develops a portfolio of oncology products resulting from an innovative therapeutic strategy focused on inhibiting the cellular functions of the AAC-11 protein.

Key Points: 
  • Created in 2021, Jalon Therapeutics develops a portfolio of oncology products resulting from an innovative therapeutic strategy focused on inhibiting the cellular functions of the AAC-11 protein.
  • Jalon Therapeutics has developed peptides which, acting as molecular decoys inside the cell, block these interactions.
  • In addition, Jalon Therapeutics peptides bind to AAC-11 partners also present in the membrane of tumor cells, triggering their destruction by membranolysis.
  • Furthermore, Jalon Therapeutics is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer.

Mnemo Therapeutics Launches RHU Project in Collaboration with Leading European Research Partners, Institut Curie and MEARY Cell and Gene Therapy Center, AP-HP

Retrieved on: 
Monday, June 13, 2022
Leadership, RHU, Cell, Research, Biotechnology, Responsibility, Gene, SUV39H1, Multimedia, Saint Louis Hospital (Bangkok), Therapy, Memory, Patient, Hospital, Technology, Laboratory, Immune system, Phenotype, Curie Institute (Paris), AP-HP, Cancer, Pharmaceutical industry, Vaccine, Mnemos EP, Princeton University

PARIS, June 13, 2022 /PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, today announced the kick-off of their participation in the prestigious Hospital-University Research in Health (RHU) program. Designed by France's National Research Agency, the RHU funding supports cutting-edge research and cross-institutional collaborations, bringing together academia, businesses, and hospitals to push the boundaries of what is possible in healthcare.

Key Points: 
  • Designed by France's National Research Agency, the RHU funding supports cutting-edge research and cross-institutional collaborations, bringing together academia, businesses, and hospitals to push the boundaries of what is possible in healthcare.
  • Among them, receiving close to 10 million euros, is the EpCART project.
  • "We are honored to be named a laureate for this prestigious initiative and work alongside our long-standing partners at Institut Curie, as well as the MEARY Cell and Gene Therapy Center at Saint-Louis Hospital, AP-HP," said Mnemo CEO, Robert LaCaze.
  • Over the next five years, the EpCART project will seek to clinically validate this technology as an autologous therapy.

Cibiltech announces the first patient enrolled in its international clinical trial for monitoring kidney transplant patients using artificial intelligence

Retrieved on: 
Thursday, February 24, 2022
Technology, Biotechnology, Health, Other Health, Surgery, Other Science, Other Technology, Research, Medical Devices, Software, Hospitals, Science, Data Management, Clinical Trials, Saint Louis Hospital (Bangkok), Physician, Algorithm, Probability, IBox, IIA, Clinical trial, MDR, CIBIL, Adoption, Software, INSERM, Decision-making, Patient, AI, Technology, Survival, Solution, CEO, Hospital, Medical device, Dentistry

Cibiltech announced today that the first patient has been enrolled in the CIBIL clinical trial Clinical Impact of the iBox as an early Intervention tool.

Key Points: 
  • Cibiltech announced today that the first patient has been enrolled in the CIBIL clinical trial Clinical Impact of the iBox as an early Intervention tool.
  • A prospective randomized controlled trial to assess the use of a software predicting allograft survival in the follow-up of kidney transplanted patients (NCT05112315).
  • This marks the beginning of this first-of-its-kind clinical trial conducted in Europe evaluating a digital health solution.
  • The CIBIL study aims to provide clinical and health economic evidence to allow further deployment of Predigraft in Europe.

Innovative Cancer Treatments, Research in Regenerative Medicine and Gene Therapy to Be Presented at World Cord Blood Day 2021

Retrieved on: 
Tuesday, October 19, 2021
Temperature, Foundation, NMDP, Nursing, Bone marrow, Stroke, Partner, Hospital, Transplant, Lymphoma, UCSF Benioff Children's Hospital, Royal Manchester Children's Hospital, Autism, Cerebral palsy, Social media, Method, FACT, Regenerative medicine, Research, Laboratory, Parent, Saint Louis Hospital (Bangkok), University, World Marrow Donor Association, University of Minnesota, Leukemia, Accreditation, Blood, Fred Hutchinson Cancer Research Center, Thalassemia, Sickle cell disease, Cas9, Student, Medical device

TUCSON, Ariz., Oct. 19, 2021 /PRNewswire/ --Register now for the World Cord Blood Day 2021 virtual conference to be held on November 15th, 2021 ( register free via Eventbrite open to the public).

Key Points: 
  • TUCSON, Ariz., Oct. 19, 2021 /PRNewswire/ --Register now for the World Cord Blood Day 2021 virtual conference to be held on November 15th, 2021 ( register free via Eventbrite open to the public).
  • The World Cord Blood Day 2021 ( www.WorldCordBloodDay.org ) virtual conference will provide an opportunity for healthcare professionals, expectant parents, students and the general public to learn about life-saving cord blood stem cells via a mix of livestream and on-demand sessions.
  • In the on-demand sessions, pioneering cord blood research will be presented in the emerging fields of gene therapy (CRISPR/Cas9) to treat sickle cell disease and regenerative medicine to potentially treat autism, cerebral palsy, stroke and more.
  • For over forty years, QuickSTAT has been entrusted with transporting human organs and tissue for transplant or research, blood, blood products, cord blood, bone marrow, medical devices, and personalized medicine, 24/7/365.

Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients

Retrieved on: 
Thursday, October 14, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Product, Incidence, Roger Hawkins (drummer), Lymphocytopenia, Degenerative disease, Kyowa Hakko Kirin, Asia, Neurology, FDA, Disease, Itch, Sleep, Lymph, Research, MF, Weakness, Non-Hodgkin lymphoma, Blood, B-cell lymphoma, Engineering, Cutaneous T cell lymphoma, Medication package insert, T-cell lymphoma, Patient, Life, CC, Lymphocyte, Family, Saint Louis Hospital (Bangkok), ORR, Diagnosis, Dermatitis, Erythroderma, Vorinostat, Skin, SS, Histone deacetylase inhibitor, Kirin, Pain, Adult, Rash, NHL, CCR4, Malignancy, Mycosis fungoides, Nephrology, Hair loss, EORTC, Hospital, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Mycosis Fungoides (MF) and Sézary syndrome (SS), POTELIGEO, Kyowa Kirin, MYCOSIS FUNGOIDES (MF) AND SéZARY SYNDROME (SS), POTELIGEO, KYOWA KIRIN

Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab).

Key Points: 
  • Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab).
  • The best overall response rate (ORR) seen in the real-life study was 47.0% in MF patients and 68.3% in SS patients.
  • In contrast, the ORRb in MAVORIC was 21% and 37%, respectively.1,2 Of the 124 patients who received POTELIGEO treatment in the study, 44% were MF patients and 56% were SS patients.
  • Its heartening to see this new real world data, which reinforces what weve seen previously in clinical trials.